Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Sibutramine metabolite in phase II for sexual dysfunction

Oct. 3, 2001

NO-releasing compound for Rx of impotence is more potent than sildenafil citrate in vitro

Oct. 2, 2001

DA-8159 in clinical testing for erectile dysfunction

Oct. 1, 2001

Antinociceptive effects reported for HCT-1026 in rat model of cystitis

Oct. 1, 2001

FDA approves test that screens patients for InterStim Therapy for Urinary Control

Oct. 1, 2001

New drug for improving ED filed for approval in U.S., Mexico

Sep. 26, 2001

NCX-2111: a new NicOx NO-releasing compound for micturition disorders

Sep. 26, 2001

Phase II trial data support efficacy of duloxetine in stress urinary incontinence

Sep. 21, 2001

Muscarinic receptor binding profile of YM-905 correlated with pharmacological activity

Sep. 20, 2001

Tiagabine as a potential treatment option for overactive bladder

Sep. 20, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...